Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (973)	10/2/1999 11:45:00 AM
From: Sidney Street	Read Replies (2) \| Respond to of 4974

I agree with Peter about shooting for 5x - 10x not 50-100; the AVM I mentioned earlier bumped a little yesterday, I think on the WSJ article about "sentinel node" techniques for avoiding stripping out all lymph nodes after dx of breast cancer. AVM's working on a more conservative approach, apparently both for initial staging and then treatment: CAMBRIDGE, Mass., Aug. 4 /PRNewswire/ -- Advanced Magnetics, Inc. (Amex: AVM) today announced it has received a grant from the National Cancer Institute of the National Institutes of Health totaling $98,706 for a research project titled "Sentinel Lymph Node Staging with Magnetic Nanoparticles." "Sentinel lymph node staging is a key diagnostic tool used in breast cancer staging and diagnosis," stated Jerome Goldstein, Chairman and CEO of Advanced Magnetics. "Currently, patients who are having sentinel node staging done receive a radioactive dye at the tumor site. They then undergo a surgical procedure to follow the path of the dye to the sentinel node - the primary lymph node for tumor drainage - which is then removed and analyzed in a laboratory. Our research, using Combidex(R) magnetic resonance imaging lymph node agent and Code 7228 second-generation lymph node agent, may non- invasively provide the same information as the current surgical procedure." Mr. Goldstein continued: "We have been working with several clinicians in the field to evaluate the use of our products to assist in sentinel node staging. We feel this is an exciting opportunity for our products to make a difference in how patients are diagnosed and treated."

To: scaram(o)uche who wrote (973)	10/2/1999 10:21:00 PM
From: RWReeves	Respond to of 4974

Hmmm... long responses from Dr. Harmon are oft dangerous, so maybe it was a Good Thing. OT > Used to have the same problem with the WEBX stuff. Finally just went to a clean dedicated box for the internet with occasional batch cleaning of intruders. Been pretty lucky, few crummy word macro viruses is all so far and a heck of a lot less crashes. End OT. CORR, kinda a bimodal pipeline. You must love Integrillin first, then all else is forgiven. They seem to have a few good prospects in anti-platelet factors and I think a sleeper in signal transduction for congestive heart failure. Most of it is pre-clinical and Phase I/II. I notice their Help Wanted shows they are still heavily into screening new drug candidates as well. I like their ability (plus admittedly a lot of luck) to get Integrillin to market, and I like Vaughn Killian (ex-Marion Labs guy)since he seems to know how to survive in the cardio world where so many have bit it. CLTR could learn a few things (sorry, sorry, I promised not to talk about CLTR anymore). So I think they have a few more actual products in the pipe that will come to market. They just did a SPO to pay for marketing Integrillin, probably what dropped the stock price recently. Previously rumored to be a target of Chiron, but they could fit neatly into a couple of pharmas. SNAP, yes, agree that is their likely destiny. They'll have to pry SNAP out of my cold, dead fingers, or at least offer a reasonable premium and they can have it... RWR